Systemic Nalbuphine Versus Intravenous Regional Anesthesia

Comparison of Systemic Nalbuphine Versus Intravenous Regional Anesthesia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03150732

Enrollment

Registered

2017-05-12

Start date

2022-08-10

Completion date

2024-02-10

Last updated

2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

Comparison of systemic nalbuphine versus intravenous regional anesthesia in patients undergoing hand surgery.

Interventions

DRUGSystemic nalbuphine

Patients will receive systemic nalbuphine 10 mg

DRUGLocal nalbuphine

Patients will receive local nalbuphine 10 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Two groups

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Patients scheduled for elective unilateral hand surgery.

Exclusion criteria

* Patient refusal. * Allergy to study medications * Body mass index \> 35 kg/ m2 * Patients with sickle cell or Reynaud diseases * Patients with a history of psychiatric illness or on chronic opioids

Design outcomes

Primary

Measure	Time frame	Description
Duration of postoperative Analgesia	Postoperative 24 hours	minutes

Secondary

Measure	Time frame	Description
Diclofenac analgesic consumption	Postoperative 24 hours	mg
Cortisol level	Preoperative and at 4 hours after skin incision	Level of cortisone in blood (nmol/L)
Severity of postoperative Pain	Postoperative 24 hours	Visual Analogue Scale (VAS)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026